149 related articles for article (PubMed ID: 28405524)
1. Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice.
Fabian KP; Chi-Sabins N; Taylor JL; Fecek R; Weinstein A; Storkus WJ
Oncoimmunology; 2017; 6(3):e1290035. PubMed ID: 28405524
[TBL] [Abstract][Full Text] [Related]
2. DLK1: a novel target for immunotherapeutic remodeling of the tumor blood vasculature.
Chi Sabins N; Taylor JL; Fabian KP; Appleman LJ; Maranchie JK; Stolz DB; Storkus WJ
Mol Ther; 2013 Oct; 21(10):1958-68. PubMed ID: 23896726
[TBL] [Abstract][Full Text] [Related]
3. The EGF-like proteins DLK1 and DLK2 function as inhibitory non-canonical ligands of NOTCH1 receptor that modulate each other's activities.
Sánchez-Solana B; Nueda ML; Ruvira MD; Ruiz-Hidalgo MJ; Monsalve EM; Rivero S; García-Ramírez JJ; Díaz-Guerra MJ; Baladrón V; Laborda J
Biochim Biophys Acta; 2011 Jun; 1813(6):1153-64. PubMed ID: 21419176
[TBL] [Abstract][Full Text] [Related]
4. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
5. Similarities and differences in tissue distribution of DLK1 and DLK2 during E16.5 mouse embryogenesis.
Garcia-Gallastegi P; Ruiz-García A; Ibarretxe G; Rivero-Hinojosa S; González-Siccha AD; Laborda J; Crende O; Unda F; García-Ramírez JJ
Histochem Cell Biol; 2019 Jul; 152(1):47-60. PubMed ID: 30888503
[TBL] [Abstract][Full Text] [Related]
6. Targeting the pericyte antigen DLK1 with an alpha type-1 polarized dendritic cell vaccine results in tumor vascular modulation and protection against colon cancer progression.
McCormick AL; Anderson TS; Daugherity EA; Okpalanwaka IF; Smith SL; Appiah D; Lowe DB
Front Immunol; 2023; 14():1241949. PubMed ID: 37849752
[TBL] [Abstract][Full Text] [Related]
7. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature.
Maciag PC; Seavey MM; Pan ZK; Ferrone S; Paterson Y
Cancer Res; 2008 Oct; 68(19):8066-75. PubMed ID: 18829565
[TBL] [Abstract][Full Text] [Related]
8. IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination.
Llopiz D; Ruiz M; Infante S; Villanueva L; Silva L; Hervas-Stubbs S; Alignani D; Guruceaga E; Lasarte JJ; Sarobe P
Oncotarget; 2017 Jan; 8(2):2659-2671. PubMed ID: 27926522
[TBL] [Abstract][Full Text] [Related]
9. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
[TBL] [Abstract][Full Text] [Related]
10. The proteins DLK1 and DLK2 modulate NOTCH1-dependent proliferation and oncogenic potential of human SK-MEL-2 melanoma cells.
Nueda ML; Naranjo AI; Baladrón V; Laborda J
Biochim Biophys Acta; 2014 Nov; 1843(11):2674-84. PubMed ID: 25093684
[TBL] [Abstract][Full Text] [Related]
11. Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model.
Zheng F; Dang J; Zhang H; Xu F; Ba D; Zhang B; Cheng F; Chang AE; Wicha MS; Li Q
J Immunother; 2018 Oct; 41(8):361-368. PubMed ID: 30063587
[TBL] [Abstract][Full Text] [Related]
12. PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.
Rekoske BT; Smith HA; Olson BM; Maricque BB; McNeel DG
Cancer Immunol Res; 2015 Aug; 3(8):946-55. PubMed ID: 26041735
[TBL] [Abstract][Full Text] [Related]
13. The NG2 Proteoglycan in Pericyte Biology.
Stallcup WB
Adv Exp Med Biol; 2018; 1109():5-19. PubMed ID: 30523586
[TBL] [Abstract][Full Text] [Related]
14. The novel gene EGFL9/Dlk2, highly homologous to Dlk1, functions as a modulator of adipogenesis.
Nueda ML; Baladrón V; García-Ramírez JJ; Sánchez-Solana B; Ruvira MD; Rivero S; Ballesteros MA; Monsalve EM; Díaz-Guerra MJ; Ruiz-Hidalgo MJ; Laborda J
J Mol Biol; 2007 Apr; 367(5):1270-80. PubMed ID: 17320102
[TBL] [Abstract][Full Text] [Related]
15. Excess vascular endothelial growth factor-A disrupts pericyte recruitment during blood vessel formation.
Darden J; Payne LB; Zhao H; Chappell JC
Angiogenesis; 2019 Feb; 22(1):167-183. PubMed ID: 30238211
[TBL] [Abstract][Full Text] [Related]
16. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
17. Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.
Villarreal DO; Chin D; Smith MA; Luistro LL; Snyder LA
Oncotarget; 2017 Jun; 8(24):39117-39130. PubMed ID: 28388572
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8
Zahm CD; Colluru VT; McNeel DG
Cancer Immunol Res; 2017 Aug; 5(8):630-641. PubMed ID: 28634215
[TBL] [Abstract][Full Text] [Related]
19. Delta-like 2 negatively regulates chondrogenic differentiation.
Xu W; Wang Y; Zhao H; Fan B; Guo K; Cai M; Zhang S
J Cell Physiol; 2018 Sep; 233(9):6574-6582. PubMed ID: 29057471
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
